腹腔与静脉紫杉醇联合替吉奥一线治疗胃癌腹膜转移的III期随机临床试验
DRAGON-01研究为多中心开放标签III期优效性试验,纳入胃癌腹膜转移初治患者,按2:1随机接受腹腔+静脉紫杉醇联合替吉奥(IP组)或静脉紫杉醇联合替吉奥(PS组)。
要点
- 腹腔+静脉紫杉醇联合替吉奥较静脉方案显著延长总生存(19.4 vs 13.9个月,HR 0.67)
- 中位无进展生存亦获益(11.2 vs 7.2个月,HR 0.72,95%CI 0.54-0.96)
- 3/4级不良事件发生率IP组38.5%、PS组41.9%,未增加严重毒性,无治疗相关死亡
核心结论
- 在胃癌腹膜转移初治患者中,腹腔+静脉紫杉醇联合替吉奥较静脉紫杉醇联合替吉奥显著改善总生存,且未增加严重毒性,为一线腹腔治疗提供积极信号。
研究设计与样本
- 多中心、开放标签、随机III期优效性临床试验(DRAGON-01),中国9家医院,2017年5月至2022年3月入组,数据截止2025年3月11日。
- 纳入成人胃腺癌、腹腔镜确诊腹膜转移、无腹膜外转移且未接受过系统治疗者。
- 共246例评估,238例(96.7%)按2:1随机分组,222例(90.2%)接受治疗并纳入主要分析。
主要发现
- 中位随访72.2个月(IQR 50.8-80.2),IP组中位总生存19.4个月(95%CI 17.1-22.9),PS组13.9个月(95%CI 10.3-16.1)。
- 中位无进展生存IP组11.2个月(95%CI 9.3-14.0),PS组7.2个月(95%CI 5.7-11.6),HR 0.72(95%CI 0.54-0.96)。
- 3/4级不良事件IP组57例(38.5%)、PS组31例(41.9%),无治疗相关死亡。
关键数值与推荐
- IP组方案:紫杉醇静脉50 mg/m2+腹腔20 mg/m2,第1、8天,每21天周期;替吉奥口服80 mg/m2,每日一次,第1-14天。
- PS组方案:紫杉醇静脉70 mg/m2,第1、8天;替吉奥口服80 mg/m2,每日一次,第1-14天。
- 主要终点为总生存,次要终点包括无进展生存和安全性。
临床怎么用
- 对于腹膜转移的胃腺癌初治患者,可考虑在静脉紫杉醇联合替吉奥基础上加用腹腔紫杉醇,以改善生存且不显著增加严重毒性。
- 该方案需腹腔给药操作,临床实施应确保中心具备相应技术条件并监测腹腔化疗相关并发症。
局限性
- 开放标签设计可能引入偏倚。
- 研究仅在中国9家医院开展,外部推广性需进一步验证。
- 入组患者为腹腔镜确诊腹膜转移且无腹膜外转移,不适用于更广泛人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Gastric cancer with peritoneal metastasis has a poor prognosis, and survival with commonly used regimens, such as intravenous paclitaxel plus S-1 (an oral fluoropyrimidine), remains limited. Whether intraperitoneal paclitaxel, which achieves high drug concentrations in the peritoneal cavity, can improve survival has not been established in a phase 3 randomized clinical trial. OBJECTIVE: To determine whether adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improves overall survival in gastric cancer with peritoneal metastasis. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, randomized phase 3 superiority clinical trial (DRAGON-01) was conducted in 9 hospitals in China. Enrollment went from May 2017 to March 2022, and the data cutoff was March 11, 2025. The trial included adults with gastric adenocarcinoma and laparoscopically confirmed peritoneal metastasis without extraperitoneal metastases or prior systemic therapy. INTERVENTIONS: The IP group received paclitaxel, 50 mg/m2, intravenously plus 20 mg/m2, intraperitoneally on days 1 and 8 of each 21-day cycle, with oral S-1, 80 mg/m2, once per day on days 1 to 14. The PS group received paclitaxel, 70 mg/m2, intravenously on days 1 and 8, with S-1 80, mg/m2, once per day on days 1 to 14. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival. Secondary end points included progression-free survival and safety. RESULTS: Among 222 treated patients (median [IQR] age, 59 [48-66] years; 104 [46.8%] female individuals and 118 [53.2%] male individuals), median (IQR) follow-up was 72.2 (50.8-80.2) months. Of 246 who were assessed, 238 (96.7%) were randomized 2:1 to receive intraperitoneal and intravenous paclitaxel plus oral S-1 (IP group) or intravenous paclitaxel plus S-1 (PS group); 222 (90.2%) received treatment (primary analysis). Median overall survival was 19.4 months (95% CI, 17.1-22.9) in the IP group and 13.9 months (95% CI, 10.3-16.1) in the PS group (hazard ratio, 0.67; 95% CI, 0.50-0.90; P = .01). Median progression-free survival was 11.2 months (95% CI, 9.3-14.0) vs 7.2 months (95% CI, 5.7-11.6) (hazard ratio, 0.72; 95% CI, 0.54-0.96). Grade 3 or 4 adverse events occurred in 57 (38.5%) in the IP group and 31 (41.9%) in the PS group; no treatment-related deaths occurred. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial of patients with gastric cancer with peritoneal metastasis suggest that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 significantly improved overall survival without increasing severe toxic effects, potentially providing an encouraging signal for IP therapy in first-line treatment of gastric cancer with peritoneal metastasis. TRIAL REGISTRATION: chictr.org.cn Identifier: ChiCTR-IIR-16009802.
引用
- Yan C, Yang Z, Shi Z, et al. Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 42166134. doi:10.1001/jamaoncol.2026.1347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。